Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marius M Hoeper

Showing results (251-260 of 311) with videos related to

Pageof 32
Sort By:
American Journal of Respiratory and Critical Care Medicine|September 3, 2014
Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosisMike O Becker, Angela Kill, Marissa Kutsche, et al.
ERJ Open Research|December 10, 2025
Survival in patients with chronic thromboembolic pulmonary hypertension treated with riociguat <i>versus</i> other medications: a COMPERA analysisMatthias Held, Christine Pausch, Doerte Huscher, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|March 21, 2021
Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP studySteven D Nathan, Vincent Cottin, Juergen Behr, et al.
BMC Pulmonary Medicine|December 29, 2017
Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access studyVallerie V McLaughlin, Pavel Jansa, Jens E Nielsen-Kudsk, et al.
Radiology|January 5, 2021
Imaging of Pulmonary Hypertension in Adults: A Position Paper from the Fleischner SocietyMartine Remy-Jardin, Christopher J Ryerson, Mark L Schiebler, et al.
American Journal of Respiratory and Critical Care Medicine|March 4, 2025
Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in <i>BMPR2</i> Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR)David Montani, Vallerie V McLaughlin, J Simon R Gibbs, et al.
Circulation|February 14, 2013
Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES studyMarius M Hoeper, Robyn J Barst, Robert C Bourge, et al.
The European Respiratory Journal|January 6, 2021
Imaging of pulmonary hypertension in adults: a position paper from the Fleischner SocietyMartine Remy-Jardin, Christopher J Ryerson, Mark L Schiebler, et al.
The Lancet. Respiratory Medicine|February 23, 2025
Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patientsFranck F Rahaghi, Marc Humbert, Marius M Hoeper, et al.
The European Respiratory Journal|September 11, 2023
Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trialRogerio Souza, David B Badesch, H Ardeschir Ghofrani, et al.
Pageof 32

Showing results (251-260 of 311) with videos related to

Sort By:
Pageof 32
American Journal of Respiratory and Critical Care Medicine|September 3, 2014
Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosisMike O Becker, Angela Kill, Marissa Kutsche, et al.
ERJ Open Research|December 10, 2025
Survival in patients with chronic thromboembolic pulmonary hypertension treated with riociguat <i>versus</i> other medications: a COMPERA analysisMatthias Held, Christine Pausch, Doerte Huscher, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|March 21, 2021
Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP studySteven D Nathan, Vincent Cottin, Juergen Behr, et al.
BMC Pulmonary Medicine|December 29, 2017
Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access studyVallerie V McLaughlin, Pavel Jansa, Jens E Nielsen-Kudsk, et al.
Radiology|January 5, 2021
Imaging of Pulmonary Hypertension in Adults: A Position Paper from the Fleischner SocietyMartine Remy-Jardin, Christopher J Ryerson, Mark L Schiebler, et al.
American Journal of Respiratory and Critical Care Medicine|March 4, 2025
Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in <i>BMPR2</i> Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR)David Montani, Vallerie V McLaughlin, J Simon R Gibbs, et al.
Circulation|February 14, 2013
Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES studyMarius M Hoeper, Robyn J Barst, Robert C Bourge, et al.
The European Respiratory Journal|January 6, 2021
Imaging of pulmonary hypertension in adults: a position paper from the Fleischner SocietyMartine Remy-Jardin, Christopher J Ryerson, Mark L Schiebler, et al.
The Lancet. Respiratory Medicine|February 23, 2025
Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patientsFranck F Rahaghi, Marc Humbert, Marius M Hoeper, et al.
The European Respiratory Journal|September 11, 2023
Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trialRogerio Souza, David B Badesch, H Ardeschir Ghofrani, et al.
Pageof 32